AMY KUO: Open Payments
NPI 1861143752 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,655 in 43 payments from 14 companies in 2025. Trend: 2023 $444 · 2024 $1,093 · 2025 $1,655
Food & beverage: $1,655
| Company | Payments | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 3 | $316 |
| Daiichi Sankyo Inc. | 12 | $270 |
| E.R. Squibb & Sons, L.L.C. | 2 | $254 |
| AstraZeneca Pharmaceuticals LP | 10 | $196 |
| Janssen Biotech, Inc. | 2 | $158 |
| Rigel Pharmaceuticals, Inc. | 2 | $146 |
| Merck Sharp & Dohme LLC | 4 | $116 |
| Celgene Corporation | 2 | $34 |
| BeOne Medicines USA, Inc. | 1 | $31 |
| Kite Pharma, Inc. | 1 | $31 |
Products named: REVUFORJ, CALQUENCE, Vanflyta, OPDIVO, RYBREVANT, BREYANZI, REZLIDHIA, KEYTRUDA.
Industry payments across CA — which companies pay providers there.
